PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Bibliographic Details
Main Authors:	J. C. Barrientos, P. M. Barr, A. R. Mato, C. S. Tam, P. Ghia, C. Moreno, N. E. Kay, T. Siddiqi, E. Szafer-Glusman, C. Zhou, L. Neumayr, G. Krigsfeld, W. G. Wierda, T. Shanafelt
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000850364.78915.d9

Similar Items

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
by: A. R. Mato, et al.
Published: (2022-06-01)

S144: IMMUNE RESTORATION AND SYNERGISTIC ACTIVITY WITH FIRST-LINE (1L) IBRUTINIB (IBR) PLUS VENETOCLAX (VEN): TRANSLATIONAL ANALYSES OF CAPTIVATE PATIENTS WITH CLL
by: I. Solman, et al.
Published: (2022-06-01)

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY
by: Paolo Ghia, et al.
Published: (2023-08-01)

P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT
by: C. Moreno, et al.
Published: (2022-06-01)

Rituximab and Fludarabine or Cyclophosphamide Combination Treatment for Older Waldenström Macroglobulinemia Patients
by: Xiaowei Xu, et al.
Published: (2013-12-01)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
by: James D’Rozario, et al.
Published: (2019-05-01)

Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
by: Osterborg, A, et al.
Published: (2012)

Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population
by: Stefano Molica, et al.
Published: (2024-03-01)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
by: Pin Lu, et al.
Published: (2021-02-01)

P670: ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V)
by: L. J. Croner, et al.
Published: (2022-06-01)

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
by: Mandrik O, et al.
Published: (2015-08-01)

P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTUZUMAB +/- IBRUTINIB: POOLED ANALYSIS OF 13 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN GCLLSG TRIALS
by: P. Cramer, et al.
Published: (2022-06-01)

Do not treat all CLL patients with fludarabine
by: Bosanquet, A, et al.
Published: (1998)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial
by: Dena R Howard, et al.
Published: (2017-05-01)

Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide.
by: Catovsky, D, et al.
Published: (2004)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
by: J. P. Sharman, et al.
Published: (2022-06-01)

P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION
by: Thomas Kipps, et al.
Published: (2023-08-01)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
by: Karoline Kielbassa, et al.
Published: (2023-08-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Long-term survival after fludarabine, cyclophosphamide, and rituximab treatment in previously untreated chronic lymphocytic leukemia patients
by: Shokhan Mohammad Mustafa, et al.
Published: (2021-01-01)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
by: Martin Gauthier, et al.
Published: (2019-08-01)

Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
by: Karasavvidou Foteini, et al.
Published: (2011-07-01)

Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.
by: Hudson, E, et al.
Published: (2008)

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY
by: L. E. Roeker, et al.
Published: (2022-06-01)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
by: Yi Miao, et al.
Published: (2023-08-01)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
by: Lydia Scarfò, et al.
Published: (2023-08-01)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020-08-01)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
by: Vincenzo Maria Perriello, et al.
Published: (2023-05-01)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

High mortality of DiSC assay-resistant CLL patients treated with fludarabine.
by: Bosanquet, A, et al.
Published: (1998)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
by: Marco Montillo, et al.
Published: (2008-03-01)

Evaluación económica de rituximab en combinación con fludarabina y ciclofosfamida en comparación con fludarabina y ciclofosfamida en el tratamiento de la leucemia linfática crónica Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia
by: Luis Felipe Casado, et al.
Published: (2011-08-01)

Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient
by: Kim Abbegail Tan Aldecoa, et al.
Published: (2023-01-01)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
by: Natalia Timofeeva, et al.
Published: (2021-04-01)

Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
by: Alessandra Petrillo, et al.
Published: (2022-06-01)